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Amajor challenge to global malaria control and elimination is early detection and containment of emerging drug resistance.
Next-generation sequencing (NGS) methods provide the resolution, scalability, and sensitivity required for high-throughput
surveillance of molecular markers of drug resistance. We have developed an amplicon sequencing method on the Ion Torrent
PGM platform for targeted resequencing of a panel of six Plasmodium falciparum genes implicated in resistance to first-line
antimalarial therapy, including artemisinin combination therapy, chloroquine, and sulfadoxine-pyrimethamine. The protocol
was optimized using 12 geographically diverse P. falciparum reference strains and successfully applied to multiplexed sequenc-
ing of 16 clinical isolates from India. The sequencing results from the reference strains showed 100% concordance with previ-
ously reported drug resistance-associated mutations. Single-nucleotide polymorphisms (SNPs) in clinical isolates revealed a
number of known resistance-associated mutations and other nonsynonymous mutations that have not been implicated in drug
resistance. SNP positions containing multiple allelic variants were used to identify three clinical samples containing mixed geno-
types indicative of multiclonal infections. The amplicon sequencing protocol has been designed for the benchtop Ion Torrent
PGM platform and can be operated with minimal bioinformatics infrastructure, making it ideal for use in countries that are en-
demic for the disease to facilitate routine large-scale surveillance of the emergence of drug resistance and to ensure continued
success of the malaria treatment policy.
Mortality due tomalariahasdecreasedbyhalf since2000, and theglobal incidence has decreased by 37%, yet the disease remains
a significant public health burden (1). Countries with large popula-
tions in particular struggle to combat the disease with underre-
sourced and inadequate health care facilities. India, with its popu-
lation of 1.2 billion, contributes a significant number of malaria
cases each year, although it has been making significant progress
toward the goal of zero malaria cases set by the National Vector
Borne Disease Control Programme. Indeed, India is now in the
control phase of a four-phase path toward a malaria-free status,
with an aim of reaching preelimination status by 2017 (2).
One of the major threats to global malaria control is the rise
and spread of parasite resistance to antimalarial drugs. In order to
achieve preelimination status by 2017, India needs to scale up
interventions to ensure the efficacy of first-line antimalarial ther-
apy and monitor the emergence of drug-resistant parasites, par-
ticularly in areas with the highest disease burden. Effective moni-
toring of drug efficacy and surveillance of drug resistance in
regions endemic for malaria require an integrated approach com-
prising in vivo drug trials, in vitro/ex vivo drug efficacy assays, and
tracking of molecular markers of drug resistance. In vivo testing is
the gold standard to measure clinical efficacy of antimalarial
drugs, but it is expensive and difficult to implement on a regular
basis and on a large scale. In vitro assays provide an understanding
of intrinsic resistance; however, they are labor-intensive and re-
quire laboratory infrastructure for in vitro culture. In contrast,
molecularmarkers of resistance offer a simpler alternative for rou-
tine surveillance. Although these do not take into account host
immunity and drug pharmacokinetics, molecular markers can
help track the emergence of drug-resistant malaria parasites be-
fore they become clinically evident (3).
A number of molecular genotyping techniques have been de-
veloped and implemented over the last few decades for monitor-
ing drug resistance in clinical isolates. Traditional methods in-
clude restriction fragment length polymorphism (RFLP) analysis
(4), molecular beacons (5), real-time PCR (6, 7), dot blot probe
hybridization (8), and single-nucleotide primer extension (9).
More recent high-throughput methods include high-resolution
DNAmelting (HRM) (10, 11), a single-nucleotide polymorphism
(SNP)-based custom genotyping assay (12, 13), a TaqMan allelic
discrimination assay (14), mass spectrometry-based SNP geno-
typing (15), a ligase detection reaction fluorescent microsphere
(LDR-FM) assay (16), and loop-mediated isothermal amplifica-
tion (LAMP) (17). Each method comes with its own advantages
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and disadvantages, so researchers can choose a suitable technique
based on the requirements, facilities, and resources available. A
common limitation of these techniques is that while they allow the
detection of known resistance alleles of a particular gene, they do
not facilitate the discovery of novel genetic polymorphisms that
could be involved in drug resistance. Sanger sequencing of DNA
polymorphisms provides one method for identifying novel drug
resistance polymorphisms and has served as a gold standard for
the validation of molecular genotyping. However, its application
to large-scale surveillance is limited by low throughput, inability
to detect polymorphisms at minor frequencies, and the high cost
of reagents.
As a result of its high throughput, resolution, and scalability,
next-generation sequencing (NGS) has been harnessed to develop
genomic tools for understanding the genetic diversity and evolu-
tion of pathogens, characterizing transmission networks, and im-
portantly, detecting drug resistance. In addition, the development
of modestly priced benchtop sequencing instruments with high
turnover rates makes it possible to integrate NGS into countries
that are endemic for the disease. There are a number of publica-
tions that describe the application, implementation, and running
costs for the most commonly used benchtop instruments, includ-
ing performance comparisons based on technical specifications,
data quality, throughput, and overall performance, and these can
be referenced for further information (18–23). While whole-ge-
nome sequencing (WGS) of pathogen field samples is ideal, it is
impractical for analyzing hundreds of clinical samples given the
current high costs of sequencing reagents, and data storage and
manipulation requirements. In contrast, amplicon sequencing in-
volves targeted amplification of one or several loci, followed by
NGS to generate a large number of sequencing reads that can be
used to assess the genetic diversity in clinical samples. This
method is more suitable for analysis of clinical samples, as it re-
quires much less DNA than that with WGS and can utilize DNA
obtained from filter paper blood spots or small-volume collec-
tions without the need for preprocessing of samples to remove
human DNA contamination (24). Amplicon sequencing of single
genomic loci has been used to identify parasite haplotypes in Plas-
modium falciparum by 454 pyrosequencing of the circumsporo-
zoite protein gene (25, 26), and to detect genetic signatures of
Plasmodium vivax relapse by Ion Torrent Personal Genome Ma-
chine (PGM) sequencing of the merozoite surface protein-1 locus
(27).
In this paper, we describe a novel protocol for Ion Torrent
PGM amplicon sequencing of a panel of P. falciparum drug resis-
tance genes, based upon a method developed by Daum et al. (28,
29) to evaluateMycobacterium tuberculosis drug resistance in clin-
ical strains. Our panel of P. falciparum drug resistance markers
includes genes implicated in resistance to artemisinin derivatives,
sulfadoxine-pyrimethamine, chloroquine, and other drugs. The
protocol was tested first on 12 publicly available P. falciparum
reference strains and subsequently applied to clinical isolates from
patients in India, with the ultimate goal of establishing it as a
routine surveillance method in a country that is endemic for the
disease.
MATERIALS AND METHODS
Ethics statement. The clinical samples examined in this study were col-
lected after ethical approval from the New York University institutional
review board (study no. i10-00173) and the ethics committee of Ispat
General Hospital, Raurkela, India.
P. falciparum reference strains. Genomic DNA from P. falciparum
strains NF54 E (MRA-1000G), TM91C235 (MRA-206G), Dd2 (MRA-
150G), 7G8 (MRA-152G), HB3 (MRA-155G), W2 (MRA-157G), K1
(MRA-159G), V1/S (MRA-176G),D10 (MRA-201G),GB4 (MRA-925G),
D6 (MRA-285G), and FCB (MRA-309G) was obtained from the Malaria
Research and Reference Reagents Resource (MR4, Manassas, VA, USA).
The geographical location and drug resistance phenotype of the strains
(where known) are shown in Table 1.
P. falciparum clinical isolates. Parasite isolates were obtained from
16 patients admitted to IspatGeneralHospital (IGH) inRaurkela,Odisha,
India, between August 2014 and January 2015, and as part of the National
Institutes of Health-funded International Center of Excellence inMalaria
TABLE 1 Geographical origin, source, and drug resistance phenotype of 12 P. falciparum laboratory reference strains and 16 P. falciparum clinical
isolates from Raurkela, India
Sample name(s) Geographical origin Source
Drug resistance
phenotypea
Reference(s)CQ SUL PYR
NF54 E The Netherlands; presumed African origin MR4 S S S 85
TM91C235 Thailand MR4 R R R 86
Dd2 Indochina MR4 R R R 85
7G8 Brazil MR4 R S R 85
HB3 Honduras MR4 S S R 85
W2 Indochina MR4 R R R 86
K1 Thailand MR4 R R R 85
V1/S Vietnam MR4 R R R 85
D10 Papua New Guinea MR4 S S S 55, 72, 87
GB4 Ghana MR4 R NA NA 88
D6 Sierra Leone MR4 S S S 85
FCB Colombia MR4 R NA S 85
RKL9610, RKL10551, RKL10868, RKL12330,
RKL50072, RKL50617, RKL58812, RKL58925,
RKL59175, RKL59290, RKL59796, RKL60303,
RKL60308, RKL60355, RKL61495, RKL64249
Ispat General Hospital, Raurkela, India Clinical isolates NA NA NA
a S, sensitive; R, resistant; NA, not available.
Amplicon Sequencing To Survey Malaria Drug Resistance
June 2016 Volume 54 Number 6 jcm.asm.org 1501Journal of Clinical Microbiology
Research (ICEMR) (30). Malaria transmission in the Raurkela area is
seasonal meso-/hyperendemic, with P. falciparum as the major infecting
species. Patients were enrolled after obtaining informed consent and
treated with antimalarials, as per the Indian national guidelines (31). An
average of 5 ml of blood was collected in EDTA Vacutainers (Thermo
Fisher Scientific, MA, USA) from each subject and centrifuged at 1,500
g for 15min at room temperature. Plasma and platelets were removed and
pelleted infected red blood cells stored at 80°C until DNA extraction.
Four of the samples were leukocyte depleted before storage: one sample
(RKL59796) was passed through a CF11 filtration column (Sigma-Al-
drich, MO, USA), and three samples (RKL64249, RKL50072, and
RKL12330) were passed through Plasmodipur filters (EuroProxima, The
Netherlands). DNA was extracted from each of the 16 samples using the
QIAampDNAbloodMIDI kit (Qiagen, CA, USA), according to theman-
ufacturer’s instructions.
Primer design. Oligonucleotide primers (see Table S1 in the sup-
plemental material) spanning six P. falciparum genes, kelch pro-
tein Pfk13 (PF3D7_1343700), chloroquine resistance transporter Pfcrt
(PF3D7_0709000), bifunctional dihydrofolate reductase-thymidylate syn-
thase Pfdhfr-ts (PF3D7_0417200), hydroxymethyldihydropterin pyrophos-
phokinase-dihydropteroate synthetasePfpppk-dhps (PF3D7_0810800),mul-
tidrug resistance protein Pfmdr1 (PF3D7_0523000), and multidrug resi
stance-associated protein-1 Pfmrp1 (PF3D7_0112200) were designed with
Primer3 (32) using the 3D7 reference assembly version 3.0 from the ma-
laria database PlasmoDB (33). The Integrated DNA Technologies (IDT)
OligoAnalyzer software was used to calculate the melting temperature
(Tm), and for homo- and heterodimer analysis, and NCBI Primer-BLAST
(34) was used to test species specificity. All oligonucleotides were synthe-
sized by Sigma-Aldrich, USA.
Gene amplification. Amplification reactions were carried out with 5
ng of MR4 reference strain DNA or 2 l of clinical isolate DNA as the
template in a 25-l reaction volume with Phusion high-fidelity PCRmas-
ter mix, HF buffer (Thermo Fisher Scientific), and a 0.2 M concentra-
tion of forward and reverse primers. The cycling parameters used to am-
plify all loci were as follows: 98°C for 30 s, 35 cycles of (98°C for 10 s and
64°C for 5 min 30 s) (35), with a final extension at 64°C for 10 min.
Amplicons were visualized on a 1% agarose gel stained with ethidium
bromide, using a GeneRuler 1-kb Plus DNA ladder (Thermo Fisher Sci-
entific). PCR products from a single sample were pooled and purified
using the QIAquick PCR purification kit (Qiagen, CA, USA) and quanti-
fied using a Qubit double-stranded DNA (dsDNA) HS assay kit (Thermo
Fisher Scientific) on the Qubit 2.0 fluorometer (Thermo Fisher Scien-
tific).
Library preparation and amplicon sequencing. A total of 500 ng of
purified pooled PCR product from each sample was used to prepare frag-
ment libraries using the NEBNext Fast DNA fragmentation and library
prep set for Ion Torrent (New England BioLabs, MA, USA). Ion Xpress
barcode adapters 1 to 28 (Thermo Fisher Scientific) were used to facilitate
multiplexing of 28 samples for each sequencing run. Libraries were size
selected usingAgencourt AMPureXPbeads (BeckmanCoulter, CA,USA)
and amplified with Q5 polymerase (New England BioLabs). Qualitative
assessment of the libraries was carried out on the Agilent 2200 Tape-
Station system (Agilent Technologies, CA, USA) using high-sensitivity
D1000 reagents (Agilent Technologies), to ensure proper size selection
and absence of adaptor/primer dimers. Fragment libraries were then
quantified on a Roche LightCycler 480 instrument II (Roche Diagnostics,
Indianapolis, IN, USA) using the complete library quantification kit op-
timized for the Roche LightCycler 480 (Kapa Biosystems, MA, USA), and
an equimolar pool of barcoded libraries was created. The library pool was
templated on Ion Sphere particles using the IonPGMHi-QOT2kit on the
Ion OneTouch 2 system (Thermo Fisher Scientific). Template-positive
Ion Sphere particles were then enriched using the Ion OneTouch ES and
loaded onto an Ion 318Chip using the IonTorrent PGMHi-Q sequencing
kit for 200-bp sequencing (Thermo Fisher Scientific).
Data processing. Sequencing data were analyzed using the Ion Tor-
rent platform software (Torrent Suite version 4.6). Raw reads were de-
multiplexed and filtered using standard quality filtering parameters by the
Torrent Suite pipeline software. Read quality was assessed using the Tor-
rent Suite FastQC plugin version 0.10.1, and high-quality reads were
aligned to the reference using the Torrent Mapping Alignment Program
version 4.0. The reference data file usedwas amulti-FASTAfile containing
the complete gene sequence and 300-bp flanking regions for each ampli-
con target gene from the P. falciparum 3D7 genome using the PlasmoDB
database (33). Sequencing depth and coverage across all gene targets were
obtained using the Coverage Analysis plugin (version 4.6.0.3) (see Table
S2 in the supplemental material).
Variant calling and annotation. Variant calling (see Table S3 in the
supplemental material) was performed using low-stringency parameters
using the Ion Torrent Variant Caller plugin (version 4.6.0.7). SNP calls
were characterized using the P. falciparum 3D7 annotation and subse-
quently processed using custom filtering criteria (see Table S4 in the sup-
plemental material). Given the high average read depth (700), variants
with a read coverage of 100, quality score of 100, and SNP coverage
of readswere discarded. SNP annotationwas performedusing in-house
perl and MS Excel VBA scripts (available upon request). In the case of
multiple-nucleotide polymorphisms (MNPs) affecting the same codon, if
the difference in the SNP allele frequencies was40%, they were merged
to calculate the resulting codon change; if the difference was 40% and
the allele frequency of one of the MNPs was 10%, only the SNP with
highest allele frequency was used to determine the codon change. Only
high-quality variants were used for haplotype generation. At positions
where no variants were reported, we confirmed the presence of the refer-
ence allele by obtaining raw nucleotide counts from corresponding BAM
files using BEDTools (36). Variant calls with an SNP allele frequency
of90% were marked as heterozygous and subsequently used to classify
samples as mixed infections containing more than one parasite genotype.
RESULTS
Design of a protocol for amplicon sequencing of P. falciparum
drug resistance genes.Wedeveloped a high-throughput protocol
for multiplexed amplicon sequencing of a panel of six P. falcipa-
rum genes from clinical isolates. We chose genes associated with
different types of antimalarial drug resistance in P. falciparum, as
follows: (i) mutations in the propeller domain of the kelch gene
Pfk13 are associated with slow clearance of parasites in patients
treated with ACT and confer resistance to artemisinin in vitro; (ii)
mutations in the folate biosynthesis pathway enzymes dihydrofo-
late reductase (Pfdhfr) and dihydropteroate synthetase (Pfdhps)
are associated with resistance to the antifolates sulfadoxine and
pyrimethamine; (iii) mutations in transporters in the digestive
vacuole of malaria parasites, including the chloroquine resistance
transporter (Pfcrt) and multidrug resistance protein-1 (Pfmdr1)
are major determinants of chloroquine resistance; and (iv) muta-
tions in the parasite plasmamembrane ABC transporter (Pfmrp1)
are also associated with resistance to multiple antimalarial drugs
in P. falciparum. Single primer pairs were designed to amplify
almost the entire coding regions (2 to 3 kb) of Pfk13, Pfcrt, Pfdhfr,
and Pfdhps, whereas Pfmdr1 and Pfmrp1 each required two sets of
primers (see Table S1 in the supplemental material). We devel-
oped a two-step PCR protocol (see Materials and Methods) to
amplify all loci simultaneously from a single patient sample, as
well as an amplicon sequencing protocol optimized using DNA
from several P. falciparum laboratory reference strains (Table 1).
The reference strains were chosen because they have been studied
extensively and exhibit well-characterized polymorphisms and
drug resistance phenotypes, and they are available from the Ma-
laria Reference and Reagent Resource Center (MR4). The proto-
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col was designed such that amplicons from a single sample could
be pooled and purified in a single tube, fragmented, and barcoded
to allow multiplexing of six genes from several samples in a single
NGS run. Upon testing and validating the protocol using 12 P.
falciparum reference strains, we established its use for genotyping
of field isolates by amplicon sequencing of 16P. falciparum clinical
samples obtained from patients at Ispat General Hospital in Rau-
rkela, in the state of Odisha, India (Table 1).
Sequencing data overview and validation. We designed the
protocol for multiplexed sequencing of amplicons on an Ion Tor-
rent PGM (Fig. 1) using 200-bp read chemistry and the 318 Chip.
We obtained 2.5 million usable reads from a single run, with
roughly 92,000 reads per sample and amean read length of 168 bp
(see Table S2 in the supplemental material). All data were aligned
against the P. falciparum 3D7 strain, with an average alignment
rate of 95.5% and a mean depth of coverage of 700 for each
sample (the cumulative length of the target genes was 20 kb).
Coverage plots depicting read depth across the length of each tar-
get gene revealed comparable read distribution between P. falcip-
arum reference strains (Fig. 2A) and clinical isolates (Fig. 2B),
indicating that there was no sequencing bias associated with the
clinical samples. The depth of coverage was comparable across all
target genes, except the Pfcrt gene, most likely due to the presence
of 12 high-AT homopolymer-rich introns in this gene, which are
prone to sequencing errors. Variant calling and filtration gener-
ated a total of 342 high-quality coding SNPs (see Table S4 in the
supplemental material) and 209 noncoding SNPs in the 28 P. fal-
ciparum samples. In order to validate that our method was able to
reliably detect known variations, we compared the data with pre-
viously characterized mutations for the 12 P. falciparum reference
strains in the data set. In the absence of reported variants at se-
lected positions, we confirmed the presence of the reference allele
by analyzing the raw data. Our results showed 100% concordance
with previously published data for all laboratory reference strains.
Along with the mutations identified at key positions associated
with drug resistance, the genes exhibited additional substitutions.
The 39 additional SNPs (32 nonsynonymous and 7 synonymous)
were distributed across the six amplicons as follows: two in Pfk13,
two in Pfdhps, three in Pfdhfr, nine in Pfmrp1, 11 in Pfcrt, and 12 in
Pfmdr1 (see Table S5 in the supplemental material). SNP haplo-
typeswere deduced fromkey resistance-associated alleles in the six
target genes for the 12 reference strains and 16 clinical samples
from India (Table 2). The implications of the important resistance
mutations and haplotypes identified in our data set are described
in the context of each drug with which they are associated.
ACT. Sequence polymorphisms in the Pfk13, Pfmdr1, and
Pfmrp1 genes have been found to play a role in ACT resistance.
Artemisinin combination therapy (ACT) comprises a combina-
tion of artemisinin-derived compounds, such as artesunate or
artemether, with other longer-acting antimalarials to limit selec-
tion of parasites resistant to either drug (37). It was discovered
recently that mutations in the propeller domain of the kelch pro-
tein PfK13 are associatedwith resistance to artemisinin derivatives
in field isolates (38), and they are also able to confer in vitro resis-
tance to artemisinin, albeit in specific genetic backgrounds (39).
Amino acid substitutions in PfK13, including C580Y, Y493H, and
R539T, among others (40), have been shown to correlate with
slow clearance of parasites in patients treated with ACT in field
isolates from Cambodia (38). Another Pfk13 mutation, M476I,
was identified in laboratory strains that acquired artemisinin re-
sistancewhen subjected to drug pressure (38). A past survey of 384
samples across India identified four nonsynonymous SNPs in the
FIG 1 Experimental workflow used in this study, from sample collection and processing, library preparation, amplicon sequencing, and subsequent data
analysis.
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propeller regions of the Pfk13 gene, namely, G533A, S549Y,
R561H, and A578S (41). We did not identify these or any other
nonsynonymous SNPs in the K13 propeller domain of 16 P. fal-
ciparum clinical isolates from Raurkela. The K189T substitution,
which lies outside the propeller domain, was detected in three
MR4 strains (HB3, GB4, and D6) and three clinical isolates
(RKL58812, RKL61495, and RKL50617). This substitution is
widely prevalent in African artemisinin-sensitive isolates (42–44)
FIG 2 Sequencing coverage of drug resistance genes in P. falciparum reference strains and clinical isolates. Plots show sequencing read depth (x axis) across the
amplicon length (y axis) for each of the six drug resistance genes. (A) A total of 12 P. falciparum reference strains from MR4 are shown, with each line
corresponding to a particular reference strain shown in the key on the left. (B) A total of 16 P. falciparum clinical isolates from Raurkela, India, are shown, with
each line corresponding to a particular clinical isolate shown in the key on the left.
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and has also been seen in South Asian isolates (45). Only one
synonymous SNP, L119L, was found in the isolate RKL60303.
Based on their genotype, all the clinical isolates in our study are
sensitive to artemisinin.
Artesunate (AS) is partnered with sulfadoxine-pyrimethamine
(SP), called AS-SP, in most regions in India, except the northeast-
ern region, where artemether is paired with lumefantrine (AL)
due to widespread resistance against SP (31). The wild-type alleles
of Pfmdr1 coding for the amino acids N86 and D1246 are associ-
ated with resistance to AL (46, 47). The N86F184D1246 haplotype
associated with AL treatment failure (48) was observed in seven
clinical isolates and two reference strains, HB3 and TM91C235.
The triple-mutant Pfmdr1 allele encoding the substitutions
C1034D1042Y1246, which confer increased sensitivity to artemis-
inin in vitro (49), was absent in all samples, except the 7G8 refer-
ence strain. In the case of Pfmrp1, all 16 clinical isolates and seven
of the reference strains showed the F1390 allelic variant that is
associated with decreased in vitro susceptibility to artemisinin,
mefloquine, and lumefantrine (50). The amino acid substitution
I876V in Pfmrp1, which was previously reported in recrudescent
infections in East Africa following AL treatment (51), was present
in nine clinical isolates.
SP. Sequence polymorphisms in thePfdhfr,Pfdhps, andPfmrp1
genes have been found to play a role in SP resistance. Resistance to
pyrimethamine (PYR) is most strongly associated with the S108N
substitution in Pfdhfr (52, 53), which reduces the binding of PYR
to the dihydrofolate reductase (DHFR) protein. Additional amino
acid substitutions at C59R, N51I, and I164L further increase re-
sistance to PYR (54). The triple mutant A16I51R59N108I164 and
quadruple mutant A16I51R59N108L164 confer the highest level of
resistance to PYR. These were detected in the PYR-resistant refer-
ence strains Dd2, TM91C235, V1/S, andW2. Five clinical isolates
from Raurkela contain double mutants resulting in the
A16N51R59N108I164 haplotype, which is similar to the PYR-resis-
tant K1 strain. Six isolates possess the wild-type A16N51C59S108I164
haplotype, as seen in the PYR-sensitive NF54 strain. The remain-
ing five isolates have two allelic variants at the Pfdhfr locus, as
depicted in Table 2. Five key substitutions in Pfdhps, A437G,
S436A, K540E, A581G, and A613T (55, 56), have been proposed
to reduce the binding of the PfDHPS protein to its inhibitor sul-
fadoxine (SUL). The reference strain 3D7has a single substitution,
A437G, conferringmoderate resistance to SUL (57). All 16 clinical
isolates possess the SUL-sensitive S436A437K540A581A613 haplotype,
observed in the reference strains D10, HB3, and FCB. The Pfdhfr
and Pfdhps genotypes together indicate that all the clinical isolates
are likely to be sensitive to SP chemotherapy. None of the clinical
isolates contain the K1466R substitution in Pfmrp1, which has
been proposed to increase sensitivity to SP by promoting the ef-
flux of antifolates from the cell (58).
CQ. Sequence polymorphisms in the Pfcrt and Pfmdr1 genes
have been found to play a role in CQ resistance. Resistance to CQ
is a result of key mutations in Pfcrt and Pfmdr1 that reduce the
accumulation of CQ in the parasite digestive vacuole (59, 60). The
K76T substitution in Pfcrt is strongly associated with in vitro and
in vivo resistance to CQ and is usually accompanied by additional
mutations at amino acid positions 72 to 75, 97, 220, 271, 326, 356,
and 371 (61–63). The K76T substitution was observed in seven of
the clinical isolates as part of the C72V73I74E75T76 haplotype that is
also present in a majority of the CQ-resistant reference strains.
Nine clinical isolates had the C72V73M74N75K76 haplotype present
in the CQ-sensitive strains NF54 E, D6, D10, and HB3. Interest-
ingly, the most prevalent haplotype in India is the CQ-resistant
S72V73M74N75T76 haplotype (64). However, its frequency var-
ies from the western regions of the country (where it is fixed in
the population) to the eastern regions, which are adjacent to
Southeast Asian countries, such as Myanmar (65, 66). The
S72V73M74N75T76 haplotype was not detected in any of the sam-
ples except the 7G8 reference strain from Brazil. Mutations caus-
ing substitutions in Pfmdr1 codons 86, 184, 1034, 1042, and 1246
are linked with increased resistance to CQ (59, 67). The CQ-sen-
sitive Pfmdr1 haplotype N86Y184S1034N1042D1246 was detected in
six of the clinical isolates and three reference strains, NF54 E, D6,
and D10. Four clinical isolates possessed a single substitution,
Y184F, similar to that observed in TM91C235, while three clinical
isolates had two allelic variants at the Y184 position. Three clinical
isolates had the CQ resistance-conferringN86Y substitution, sim-
ilar to the K1, V1/S, and W2 reference strains. The H191Y substi-
tution in PfMRP1, associated with increased susceptibility to CQ
(68), was seen in eight of the 16 clinical isolates and two isolates
that also had the wild-type H191 allelic variant.
Using heterozygous variants for identification of mixed ge-
notypes within samples. The depth of sequence coverage gener-
ated by the IonTorrent PGM should theoretically enable the iden-
tification of mixed-genotype populations within samples. Indeed,
during data analysis, we detected two variants, N86Y (36%) and
N86F (64%), at Pfmdr1 codon 86 in our Dd2 sample obtained
from MR4. The N86F variant has been reported in field isolates
from Africa and Afghanistan (69, 70), as well as the South Asian
reference isolate Dd2 (11, 71). It appears that the two allelic vari-
ants observed in our Dd2 sample represent two copies of Pfmdr1,
which have been observed in previous studies (11). Interestingly,
the copy number variation of Pfmdr1 has been implicated in re-
duced sensitivity to antimalarial drugs, such as CQ, mefloquine,
and lumefantrine (72–74). This finding encouraged us to use
heterozygous variant calls for the identification of multiclonal in-
fections in the clinical isolates. Samples were ranked based on the
total number of high-quality heterozygous SNPs (Fig. 3A). As
might be expected due to a loss of diversity during in vitro culture
adaptation, heterozygous SNPswere not detected inmost of the P.
falciparum reference strains. Four of the clinical isolates also did
not exhibit any heterozygous variants, indicating the presence of a
single parasitic clone in these isolates. On the other hand, the
number of heterozygous SNPs in three of the samples, RKL12330,
RKL58812, and RKL60355, wasmore than twice themedian value
observed in the entire data set (Fig. 3A). Further analysis of key
drug resistancemutationswith heterozygous variant calls revealed
that the proportion of the reference and alternate allele was con-
sistent across the various SNPs for three samples (Fig. 3B). There-
fore, we classified three of the clinical isolates asmulticlonal infec-
tions, comprising a mixture of genotypes with various drug
susceptibilities. These results demonstrate the potential of the am-
plicon sequencingmethod to estimate the complexity of infection
in P. falciparum clinical isolates. Although we only used high-
quality heterozygous variants (allele frequency, 10%) for the
purpose of this analysis, we should be able to improve the limit of
detection of our NGS approach to identify rare variants (1%)
while accounting for sequencing errors and other technical arti-
facts.
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DISCUSSION
Malaria continues to be challenging to eradicate, in part becauseP.
falciparum parasites have developed resistance to nearly every
antimalarial drug developed (75, 76). After its introduction in
1934, chloroquine (CQ) was successfully used to treat malaria
cases worldwide until the 1950s, when CQ-resistant P. falciparum
arose in Southeast Asia and South America and eventually spread
to India in the 1970s. Although its use against P. falciparum was
discontinued, CQ remained the first-line treatment for P. vivax
malaria in India (31). P. falciparum also developed resistance to
subsequent antimalarial treatments involving combinations of
antifolates, sulfadoxine, and pyrimethamine. Artemisinin combi-
nation therapy (ACT) was introduced in India in 2005, and arte-
misinin (ART) derivatives proved to be the most effective drugs
developed against P. falciparum. However, in 2008, ART resis-
tancewas identified for the first time inCambodia (77, 78) and has
spread and arisen independently in other parts of Southeast Asia
since then (79). The recent identification ofmutations in the kelch
propeller domain of the Pfk13 gene as key causal determinants of
artemisinin resistance have provided the opportunity for real-
time surveillance of the emergence and spread of ART resistance
in regions that are endemic for malaria. The detection of multiple
Pfk13 mutations associated with delayed parasite clearance in
Myanmar (80), which shares a border with Northeast India, has
raised the alarm for the spread of ART resistance to India, similar
to the suspected trajectory of CQ- and SP-resistant parasites. So
far, Pfk13 surveillance studies in India have not yet detected any
evidence for ART resistance in the country (41, 81). The success of
ACT relies on the continued efficacy of ART and its partner drugs
and is crucial for malaria control in India.
In order to address the pressing need to strengthen malaria
surveillance, we have proposed here a next-generation amplicon
sequencing method to enable high-throughput detection of ge-
netic mutations in six P. falciparum genes associated with antima-
larial drug resistance in India. Themethod can be easily adapted to
include other candidate genes depending on the malaria treat-
ment regimen used across different regions that are endemic for
the disease. While most traditional surveillance methods focus on
the detection of a limited number of known polymorphisms, our
method involves sequencing the entire gene, which facilitates the
FIG 3 Estimation of mixed genotypes using heterozygous variant calls. (A) Plot showing number of high-quality heterozygous variant calls (y axis) for each P.
falciparum sample (x axis). Isolates on the left of the vertical dotted line, which represents twice the median number of heterozygous variants observed in the
entire data set, were classified as potentialmulticlonal infections. (B) Box plots representing the proportion of the two allelic variants (shaded or dotted) observed
in heterozygous SNPs associatedwith drug resistance in samples RKL12330, RKL58812, andRKL60355, whichwere classified asmulticlonal infections in the plot
in panel A.
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discovery of novel polymorphisms involved in drug resistance.
For example, the novel mutation (C350R) in Pfcrt, causing a re-
versal of CQ resistance conferred by the SVMNT haplotype in P.
falciparum parasites from French Guiana, would have not been
identified if only a limited number of SNPs had been analyzed
(82). Moreover, as multiple genes can be associated with resis-
tance to a single drug, the simultaneous analysis of these genes will
improve our knowledge of the possible combinatorial effects of
multiplemutations on parasite drug resistance. Bymonitoring the
molecular markers of resistance for all drugs administered in a
particular region, changes to treatment policy can be imple-
mented to contain the spread of drug resistance. This is particu-
larly relevant in the context of reintroducing old drugs in areas
where previously resistant parasites have reverted to carrying
drug-susceptible alleles in the prolonged absence of drug pressure,
as recently observed inMalawi with the return of the CQ-sensitive
wild-type Pfcrt allele in the population a decade after CQ with-
drawal (83). We also demonstrated the potential of amplicon se-
quencing to discriminate between single and multiclonal infec-
tions. As malaria parasite infections can consist of more than one
parasite clone, the presence of both drug-sensitive and drug-resis-
tant parasites within a single patient may occur. We plan to study
the variation inwithin-host diversity in response to chemotherapy
by obtaining patient samples before and after drug treatment, so
as to track changes in the frequency of individual alleles identified
in multiclonal infections. Analysis of the amplicon sequencing
results in conjunction with clinical and epidemiological data as-
sociated with the patient isolates can help us decipher the impact
of the complexity of infection on drug susceptibility or disease
phenotype.
As proof of principle, we applied the method to 28 P. falcipa-
rum samples at a cost of $95 per patient, but the technology can
allowmultiplexing of up to 96 samples in a single run, significantly
reducing the cost to approximately $73 per patient sample ($14
for DNA extraction and generation of the amplicon pool, and $59
for library preparation and sequencing). The use of the Ion Tor-
rent platform makes our technique particularly suitable in coun-
tries endemic for malaria that have limited computational infra-
structure and lack of advanced training in bioinformatics, as the
instrument comes equipped with a suite of data analysis tools for
read alignment, coverage, and variant detection that can be oper-
ated with minimum information technology expertise. As patient
blood samples can be collected, transported, and stored for a long
timewithout the need for in vitro culture, nationalmalaria control
programs could implement large-scale amplicon sequencing
studies that are not feasible using in vivo and in vitro assays. As part
of the National Institutes of Health-funded International Centers
of Excellence for Malaria Research initiative, we have set up the
Ion Torrent PGM platform at the National Institute for Malaria
Research inDelhi for in-house sequencing ofPlasmodium samples
(24).We are currently using thismethod formultiplexed sequenc-
ing of clinical isolates collected from epidemiologically diverse
sites in India (84).
ACKNOWLEDGMENTS
We thankTaraRock andTheresa TenEyck at theNYUGenomicsCore for
technical assistance, and MR4 for providing malaria parasite strains. We
also thank the director in charge and the clinical staff of Ispat General
Hospital in Raurkela for their support and dedication, as well as the di-
rector of the Institute of Life Sciences in Bhubaneswar for allowing us to
use the Infectious Disease Biology Unit in Raurkela.
This paper bears the NIMR Publication Screening Committee ap-
proval no. 011/2016.
The research reported in this publication was supported by the Na-
tional Institute of Allergy and Infectious Diseases of the National Insti-
tutes of Health under award U19AI089676 as part of the International
Centers for Excellence in Malaria Research.
The content of this paper is solely the responsibility of the authors and
does not necessarily represent the official views of the National Institutes
of Health.
FUNDING INFORMATION
This work, including the efforts of Pavitra Nagesh Rao, Swapna Uplekar,
Sriti Kayal, Prashant K Mallick, Nabamita Bandyopadhyay, Sonal Kale,
Om P Singh, Sanjib Mohanty, Samuel Crocodile Wassmer, and Jane M.
Carlton, was funded by HHS | NIH | National Institute of Allergy and
Infectious Diseases (NIAID) (U19AI089676).
REFERENCES
1. WHO/UNICEF. 2015. Achieving the malaria MDG target: reversing the
incidence of malaria 2000–2015. World Health Organization, Geneva,
Switzerland. http://apps.who.int/iris/bitstream/10665/184521/1/9789241
509442_eng.pdf?ua1.
2. WHO. 2015. India drives down malaria rates, sets sights on elimination.
World Health Organization, Geneva, Switzerland. http://www.who.int
/features/2015/india-programme-end-malaria/en/.
3. Abdul-Ghani R, Al-Maktari MT, Al-Shibani LA, Allam AF. 2014. A
better resolution for integrating methods for monitoring Plasmodium fal-
ciparum resistance to antimalarial drugs. Acta Trop 137:44–57. http://dx
.doi.org/10.1016/j.actatropica.2014.04.031.
4. Duraisingh MT, Curtis J, Warhurst DC. 1998. Plasmodium falciparum:
detection of polymorphisms in the dihydrofolate reductase and dihydrop-
teroate synthetase genes by PCR and restriction digestion. Exp Parasitol
89:1–8. http://dx.doi.org/10.1006/expr.1998.4274.
5. Durand R, Eslahpazire J, Jafari S, Delabre JF, Marmorat-Khuong A, di
Piazza JP, Le Bras J. 2000. Use of molecular beacons to detect an antifo-
late resistance-associated mutation in Plasmodium falciparum. Antimi-
crob Agents Chemother 44:3461–3464. http://dx.doi.org/10.1128/AAC
.44.12.3461-3464.2000.
6. Wilson PE, Alker AP, Meshnick SR. 2005. Real-time PCR methods for
monitoring antimalarial drug resistance. Trends Parasitol 21:278–283.
http://dx.doi.org/10.1016/j.pt.2005.04.007.
7. Alker AP, Mwapasa V, Purfield A, Rogerson SJ, Molyneux ME, Kam-
wendo DD, Tadesse E, Chaluluka E, Meshnick SR. 2005. Mutations
associated with sulfadoxine-pyrimethamine and chlorproguanil resis-
tance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimi-
crob Agents Chemother 49:3919–3921. http://dx.doi.org/10.1128/AAC
.49.9.3919-3921.2005.
8. Ranford-Cartwright LC, Johnston KL, Abdel-Muhsin AM, Khan BK,
Babiker HA. 2002. Critical comparison of molecular genotyping
methods for detection of drug-resistant Plasmodium falciparum. Trans
R Soc Trop Med Hyg 96:568–572. http://dx.doi.org/10.1016/S0035
-9203(02)90446-3.
9. Nair S, Brockman A, Paiphun L, Nosten F, Anderson TJC. 2002. Rapid
genotyping of loci involved in antifolate drug resistance in Plasmodium
falciparum by primer extension. Int J Parasitol 32:852–858. http://dx.doi
.org/10.1016/S0020-7519(02)00033-4.
10. Cruz RE, Shokoples SE, Manage DP, Yanow SK. 2010. High-throughput
genotyping of single nucleotide polymorphisms in the Plasmodium falcip-
arum dhfr gene by asymmetric PCR andmelt-curve analysis. J ClinMicro-
biol 48:3081–3087. http://dx.doi.org/10.1128/JCM.00634-10.
11. Daniels R, Ndiaye D, Wall M, McKinney J, Séne PD, Sabeti PC,
Volkman SK, Mboup S, Wirth DF. 2012. Rapid, field-deployable method
for genotyping and discovery of drug-resistance single nucleotide poly-
morphisms in Plasmodium falciparum. Antimicrob Agents Chemother
56:2976–2986. http://dx.doi.org/10.1128/AAC.05737-11.
12. Daniels R, Volkman SK, Milner DA, Mahesh N, Neafsey DE, Park DJ,
Rosen D, Angelino E, Sabeti PC, Wirth DF, Wiegand RC. 2008. A
general SNP-based molecular barcode for Plasmodium falciparum identi-
Rao et al.
1508 jcm.asm.org June 2016 Volume 54 Number 6Journal of Clinical Microbiology
fication and tracking. Malar J 7:223. http://dx.doi.org/10.1186/1475-2875
-7-223.
13. Campino S, Auburn S, Kivinen K, Zongo I, Ouedraogo J-B, Mangano
V, Djimde A, Doumbo OK, Kiara SM, Nzila A, Borrmann S, Marsh K,
Michon P, Mueller I, Siba P, Jiang H, Su X-Z, Amaratunga C, Socheat
D, Fairhurst RM, Imwong M, Anderson T, Nosten F, White NJ,
Gwilliam R, Deloukas P, MacInnis B, Newbold CI, Rockett K, Clark
TG, Kwiatkowski DP. 2011. Population genetic analysis of Plasmodium
falciparum parasites using a customized Illumina GoldenGate genotyping
assay. PLoS One 6:e20251. http://dx.doi.org/10.1371/journal.pone
.0020251.
14. Kamau E, Alemayehu S, Feghali KC, Tolbert LS, Ogutu B, Ockenhouse
CF. 2012. Development of a TaqMan allelic discrimination assay for de-
tection of single nucleotides polymorphisms associated with anti-malarial
drug resistance. Malaria J 11:23. http://dx.doi.org/10.1186/1475-2875-11
-23.
15. Ali IM, Evehe M-SB, Netongo PM, Atogho-Tiedeu B, Akindeh-Nji M,
Ngora H, Domkam IK, Diakite M, Baldip K, Ranford-Cartwright L,
Mimche PN, Lamb T, Mbacham WF. 2014. Host candidate gene poly-
morphisms and associated clearance of P. falciparum amodiaquine
and fansidar resistance mutants in children less than 5 years in Came-
roon. Pathog Glob Health 108:323–333. http://dx.doi.org/10.1179
/2047773214Y.0000000159.
16. Nankoberanyi S, Mbogo GW, LeClair NP, Conrad MD, Tumwebaze P,
Tukwasibwe S, Kamya MR, Tappero J, Nsobya SL, Rosenthal PJ. 2014.
Validation of the ligase detection reaction fluorescent microsphere assay
for the detection of Plasmodium falciparum resistance mediating poly-
morphisms in Uganda. Malar J 13:95. http://dx.doi.org/10.1186/1475
-2875-13-95.
17. Aydin-Schmidt B, Xu W, González IJ, Polley SD, Bell D, Shakely D,
Msellem MI, Björkman A, Mårtensson A. 2014. Loop mediated isother-
mal amplification (LAMP) accurately detects malaria DNA from filter
paper blood samples of low density parasitaemias. PLoS One 9:e103905.
http://dx.doi.org/10.1371/journal.pone.0103905.
18. Liu L, Li Y, Li S, Hu N, He Y, Pong R, Lin D, Lu L, Law M. 2012.
Comparison of next-generation sequencing systems. J Biomed Biotechnol
2012:251364. http://dx.doi.org/10.1155/2012/251364.
19. Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE,
Wain J, Pallen MJ. 2012. Performance comparison of benchtop high-
throughput sequencing platforms. Nat Biotechnol 30:434–439. http://dx
.doi.org/10.1038/nbt.2198.
20. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR,
Bertoni A, Swerdlow HP, Gu Y. 2012. A tale of three next generation
sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and
Illumina MiSeq sequencers. BMC Genomics 13:341. http://dx.doi.org/10
.1186/1471-2164-13-341.
21. Li X, Buckton AJ, Wilkinson SL, John S, Walsh R, Novotny T, Valas-
kova I, Gupta M, Game L, Barton PJR, Cook SA, Ware JS. 2013.
Towards clinical molecular diagnosis of inherited cardiac conditions: a
comparison of bench-top genome DNA sequencers. PLoS One 8:e67744.
http://dx.doi.org/10.1371/journal.pone.0067744.
22. McElroy K, Thomas T, Luciani F. 2014. Deep sequencing of evolving
pathogen populations: applications, errors, and bioinformatic solutions.
Microb Inform Exp 4:1. http://dx.doi.org/10.1186/2042-5783-4-1.
23. Frickmann H, Masanta WO, Zautner AE. 2014. Emerging rapid resis-
tance testing methods for clinical microbiology laboratories and their po-
tential impact onpatientmanagement. BioMedRes Int 2014:375681. http:
//dx.doi.org/10.1155/2014/375681.
24. Carlton JM, Volkman SK, Uplekar S, Hupalo DN, Pereira Alves JM, Cui
L, Donnelly M, Roos DS, Harb OS, Acosta M, Read A, Ribolla PE,
Singh OP, Valecha N, Wassmer SC, Ferreira M, Escalante AA. 2015.
Population genetics, evolutionary genomics, and genome-wide studies of
malaria: a view across the International Centers of Excellence for Malaria
Research. Am J TropMedHyg 93:87–98. http://dx.doi.org/10.4269/ajtmh
.15-0049.
25. Bailey JA, Mvalo T, Aragam N, Weiser M, Congdon S, Kamwendo D,
Martinson F, Hoffman I, Meshnick SR, Juliano JJ. 2012. Use of mas-
sively parallel pyrosequencing to evaluate the diversity of and selection on
Plasmodium falciparum csp T-cell epitopes in Lilongwe, Malawi. J Infect
Dis 206:580–587. http://dx.doi.org/10.1093/infdis/jis329.
26. Mideo N, Kennedy DA, Carlton JM, Bailey JA, Juliano JJ, Read AF.
2013. Ahead of the curve: next generation estimators of drug resistance in
malaria infections. Trends Parasitol 29:321–328. http://dx.doi.org/10
.1016/j.pt.2013.05.004.
27. Lin JT, Hathaway NJ, Saunders DL, Lon C, Balasubramanian S, Khar-
abora O, Gosi P, Sriwichai S, Kartchner L, Chuor CM, Satharath P,
Lanteri C, Bailey JA, Juliano JJ. 2015. Using amplicon deep sequencing to
detect genetic signatures of Plasmodium vivax relapse. J Infect Dis 212:
999–1008. http://dx.doi.org/10.1093/infdis/jiv142.
28. Daum LT, Rodriguez JD, Worthy SA, Ismail NA, Omar SV, Dreyer
AW, Fourie PB, Hoosen AA, Chambers JP, Fischer GW. 2012. Next-
generation Ion Torrent sequencing of drug resistance mutations inMyco-
bacterium tuberculosis Strains. 50:3831–3837.
29. Daum LT, Fourie PB, Bhattacharyya S, Ismail NA, Gradus S, Maningi
NE, Omar SV, Fischer GW. 2014. Next-generation sequencing for iden-
tifying pyrazinamide resistance inMycobacterium tuberculosis. Clin Infect
Dis 58:903–904. http://dx.doi.org/10.1093/cid/cit811.
30. Das A, Anvikar AR, Cator LJ, Dhiman RC, Eapen A, Mishra N, Nagpal
BN, Nanda N, Raghavendra K, Read AF, Sharma SK, Singh OP, Singh
V, Sinnis P, Srivastava HC, Sullivan SA, Sutton PL, Thomas MB,
Carlton JM, Valecha N. 2012. Malaria in India: the center for the study of
complex malaria in India. Acta Trop 121:267–273. http://dx.doi.org/10
.1016/j.actatropica.2011.11.008.
31. Anvikar AR, Arora U, Sonal G, Mishra N, Shahi B, Savargaonkar D,
Kumar N, Shah NK, Valecha N. 2014. Antimalarial drug policy in India:
past, present & future. Indian J Med Res 139:205–215.
32. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, RemmM,
Rozen SG. 2012. Primer3–new capabilities and interfaces. Nucleic Acids
Res 40:e115. http://dx.doi.org/10.1093/nar/gks596.
33. Bahl A, Brunk B, Crabtree J, Fraunholz MJ, Gajria B, Grant GR,
Ginsburg H, Gupta D, Kissinger JC, Labo P, Li L, Mailman MD,
Milgram AJ, Pearson DS, Roos DS, Schug J, Stoeckert CJ, Jr, Whet-
zel P. 2003. PlasmoDB: the Plasmodium genome resource. A database
integrating experimental and computational data. Nucleic Acids Res
31:212–215.
34. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL.
2012. Primer-BLAST: a tool to design target-specific primers for polymer-
ase chain reaction. BMCBioinformatics 13:134. http://dx.doi.org/10.1186
/1471-2105-13-134.
35. Su XZ, Wu Y, Sifri CD, Wellems TE. 1996. Reduced extension temper-
atures required for PCR amplification of extremely AT-rich DNA. Nu-
cleic Acids Res 24:1574–1575. http://dx.doi.org/10.1093/nar/24.8.1574.
36. Quinlan AR, Hall IM. 2010. BEDTools: a flexible suite of utilities for
comparing genomic features. Bioinformatics 26:841–842. http://dx.doi
.org/10.1093/bioinformatics/btq033.
37. White N. 1999. Antimalarial drug resistance and combination chemo-
therapy. Philos Trans R Soc Lond B Biol Sci 354:739–749. http://dx.doi
.org/10.1098/rstb.1999.0426.
38. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N,
Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S,
Suon S, Chuor CM, Bout DM, Ménard S, Rogers WO, Genton B,
Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC,
Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Ménard D. 2014.
A molecular marker of artemisinin-resistant Plasmodium falciparum ma-
laria. Nature 505:50–55.
39. Straimer J, Gnädig NF, Witkowski B, Amaratunga C, Duru V, Rama-
dani AP, Dacheux M, Khim N, Zhang L, Lam S, Gregory PD, Urnov
FD, Mercereau-Puijalon O, Benoit-Vical F, Fairhurst RM, Menard D,
Fidock DA. 2015. Drug resistance. K13-propeller mutations confer arte-
misinin resistance in Plasmodium falciparum clinical isolates. Science 347:
428–431.
40. WHO. 2015. Status report on artemisinin and ACT resistance: September
2015. World Health Organization, Geneva, Switzerland. http://www.who
.int/malaria/publications/atoz/status-rep-artemisinin-act-resistance-sept
2015.pdf?ua1.
41. Mishra N, Prajapati SK, Kaitholia K, Bharti RS, Srivastava B, Phookan
S, Anvikar AR, Dev V, Sonal GS, Dhariwal AC, White NJ, Valecha N.
2015. Surveillance of artemisinin resistance in Plasmodium falciparum in
India using the kelch13molecularmarker. AntimicrobAgents Chemother
59:2548–2553. http://dx.doi.org/10.1128/AAC.04632-14.
42. Ocholla H, Preston MD, Mipando M, Jensen AT, Campino S, MacInnis
B, Alcock D, Terlouw A, Zongo I, Oudraogo JB, Djimde AA, Assefa S,
Doumbo OK, Borrmann S, Nzila A, Marsh K, Fairhurst RM, Nosten F,
Anderson TJ, Kwiatkowski DP, Craig A, Clark TG, Montgomery J.
2014.Whole-genome scans provide evidence of adaptive evolution inMa-
Amplicon Sequencing To Survey Malaria Drug Resistance
June 2016 Volume 54 Number 6 jcm.asm.org 1509Journal of Clinical Microbiology
lawian Plasmodium falciparum isolates. J Infect Dis 210:1991–2000. http:
//dx.doi.org/10.1093/infdis/jiu349.
43. Torrentino-Madamet M, Fall B, Benoit N, Camara C, Amalvict R, Fall
M, Dionne P, Ba Fall K, Nakoulima A, Diatta B, Diemé Y, Ménard D,
Wade B, Pradines B. 2014. Limited polymorphisms in k13 gene in Plas-
modium falciparum isolates from Dakar, Senegal in 2012–2013. Malar J
13:472. http://dx.doi.org/10.1186/1475-2875-13-472.
44. Boussaroque A, Fall B, Madamet M, Camara C, Benoit N, Fall M,
Nakoulima A, Dionne P, Fall KB, Diatta B, Diémé Y, Wade B, Pradines
B. 2015. Emergence ofMutations in theK13 propeller gene ofPlasmodium
falciparum isolates from Dakar, Senegal, in 2013–2014. Antimicrob
Agents Chemother 60:624–627.
45. Wang Z, Shrestha S, Li X, Miao J, Yuan L, Cabrera M, Grube C, Yang
Z, Cui L. 2015. Prevalence of K13-propeller polymorphisms in Plasmo-
dium falciparum from China-Myanmar border in 2007–2012. Malar J 14:
168. http://dx.doi.org/10.1186/s12936-015-0672-9.
46. Sisowath C, Strömberg J, Mårtensson A, Msellem M, Obondo C,
Björkman A, Gil JP. 2005. In vivo selection of Plasmodium falciparum
pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect
Dis 191:1014–1017. http://dx.doi.org/10.1086/427997.
47. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C,
Moriera C, Price RN, Mårtensson A, Rosenthal PJ, Dorsey G, Suther-
land CJ, Guérin P, Davis TM, Ménard D, Adam I, Ademowo G, Arze C,
Baliraine FN, Berens-Riha N, Bjorkman A, Borrmann S, Checchi F,
Desai M, Dhorda M, Djimde AA, El-Sayed BB, Eshetu T, Eyase F,
Falade C, Faucher JF, Fröberg G, Grivoyannis A, Hamour S, Houze S,
Johnson J, Kamugisha E, Kariuki S, Kiechel JR, Kironde F, Kofoed PE,
LeBras J, Malmberg M, Mwai L, Ngasala B, Nosten F, Nsobya SL, Nzila
A, Oguike M, Otienoburu SD, Ogutu B, et al. 2014. Polymorphisms in
Plasmodium falciparum chloroquine resistance transporter andmultidrug
resistance 1 genes: parasite risk factors that affect treatment outcomes for
P. falciparum malaria after artemether-lumefantrine and artesunate-
amodiaquine. Am JTropMedHyg 91:833–843. http://dx.doi.org/10.4269
/ajtmh.14-0031.
48. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O’Neil
M, Milhous W, Wirth DF, Oduola AM. 2009. Selection of Plasmodium
falciparummultidrug resistance gene 1 alleles in asexual stages and game-
tocytes by artemether-lumefantrine in Nigerian children with uncompli-
cated falciparum malaria. Antimicrob Agents Chemother 53:888–895.
http://dx.doi.org/10.1128/AAC.00968-08.
49. Sidhu AB, Valderramos SG, Fidock DA. 2005. pfmdr1 mutations con-
tribute to quinine resistance and enhance mefloquine and artemisinin
sensitivity in Plasmodium falciparum. Mol Microbiol 57:913–926. http:
//dx.doi.org/10.1111/j.1365-2958.2005.04729.x.
50. Veiga MI, Ferreira PE, Jörnhagen L, Malmberg M, Kone A, Schmidt
BA, Petzold M, Björkman A, Nosten F, Gil JP. 2011. Novel polymor-
phisms in Plasmodium falciparum ABC transporter genes are associated
with major ACT antimalarial drug resistance. PLoS One 6:e20212. http:
//dx.doi.org/10.1371/journal.pone.0020212.
51. Dahlström S, Ferreira PE, Veiga MI, Sedighi N, Wiklund L, Mårtensson
A, Färnert A, Sisowath C, Osório L, Darban H, Andersson B, Kaneko A,
Conseil G, Björkman A, Gil JP. 2009. Plasmodium falciparum multidrug
resistance protein 1 and artemisinin-based combination therapy in Africa.
J Infect Dis 200:1456–1464. http://dx.doi.org/10.1086/606009.
52. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ. 1988. Amino
acid changes linked to pyrimethamine resistance in the dihydrofolate re-
ductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl
Acad Sci U SA 85:9109–9113. http://dx.doi.org/10.1073/pnas.85.23.9109.
53. Peterson DS, Walliker D, Wellems TE. 1988. Evidence that a point
mutation in dihydrofolate reductase-thymidylate synthase confers resis-
tance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A
85:9114–9118. http://dx.doi.org/10.1073/pnas.85.23.9114.
54. Gregson A, Plowe CV. 2005. Mechanisms of resistance of malaria para-
sites to antifolates. Pharmacol Rev 57:117–145. http://dx.doi.org/10.1124
/pr.57.1.4.
55. Triglia T, Menting JG, Wilson C, Cowman AF. 1997. Mutations in
dihydropteroate synthase are responsible for sulfone and sulfonamide re-
sistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 94:13944–
13949. http://dx.doi.org/10.1073/pnas.94.25.13944.
56. Wang P, Read M, Sims PF, Hyde JE. 1997. Sulfadoxine resistance in the
human malaria parasite Plasmodium falciparum is determined by muta-
tions in dihydropteroate synthetase and an additional factor associated
with folate utilization. Mol Microbiol 23:979–986. http://dx.doi.org/10
.1046/j.1365-2958.1997.2821646.x.
57. Triglia T, Wang P, Sims PF, Hyde JE, Cowman AF. 1998. Allelic
exchange at the endogenous genomic locus in Plasmodium falciparum
proves the role of dihydropteroate synthase in sulfadoxine-resistant
malaria. EMBO J 17:3807–3815. http://dx.doi.org/10.1093/emboj/17
.14.3807.
58. Dahlström S, Veiga MI, Mårtensson A, Björkman A, Gil JP. 2009.
Polymorphism in PfMRP1 (Plasmodium falciparum multidrug resistance
protein 1) amino acid 1466 associated with resistance to sulfadoxine-
pyrimethamine treatment. Antimicrob Agents Chemother 53:2553–2556.
http://dx.doi.org/10.1128/AAC.00091-09.
59. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. 2000. Pgh1
modulates sensitivity and resistance to multiple antimalarials in Plas-
modium falciparum. Nature 403:906–909. http://dx.doi.org/10.1038
/35002615.
60. Sidhu AB, Verdier-Pinard D, Fidock DA. 2002. Chloroquine resistance
in Plasmodium falciparummalaria parasites conferred by pfcrtmutations.
Science 298:210–213. http://dx.doi.org/10.1126/science.1074045.
61. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig
MT, Ursos LM, Sidhu AB, Naudé B, Deitsch KW, Su XZ, Wootton JC,
Roepe PD, Wellems TE. 2000. Mutations in the P. falciparum digestive
vacuole transmembrane protein PfCRT and evidence for their role in
chloroquine resistance. Mol Cell 6:861–871. http://dx.doi.org/10.1016
/S1097-2765(05)00077-8.
62. Djimdé A, Doumbo OK, Steketee RW, Plowe CV. 2001. Application
of a molecular marker for surveillance of chloroquine-resistant falcip-
arum malaria. Lancet 358:890–891. http://dx.doi.org/10.1016/S0140
-6736(01)06040-8.
63. Cooper RA, Ferdig MT, Su XZ, Ursos LM, Mu J, Nomura T, Fujioka H,
Fidock DA, Roepe PD, Wellems TE. 2002. Alternative mutations at
position 76 of the vacuolar transmembrane protein PfCRT are associated
with chloroquine resistance and unique stereospecific quinine and quini-
dine responses in Plasmodium falciparum.Mol Pharmacol 61:35–42. http:
//dx.doi.org/10.1124/mol.61.1.35.
64. Vathsala PG, Pramanik A, Dhanasekaran S, Devi CU, Pillai CR, Sub-
barao SK, Ghosh SK, Tiwari SN, Sathyanarayan TS, Deshpande PR,
Mishra GC, Ranjit MR, Dash AP, Rangarajan PN, Padmanaban G.
2004. Widespread occurrence of the Plasmodium falciparum chloroquine
resistance transporter (Pfcrt) gene haplotype SVMNT in P. falciparum
malaria in India. Am J Trop Med Hyg 70:256–259.
65. Mallick PK, Sutton PL, Singh R, Singh OP, Dash AP, Singh AK, Carlton
JM, Bhasin VK. 2013. Microsatellite analysis of chloroquine resistance
associated alleles and neutral loci reveal genetic structure of Indian Plas-
modium falciparum. Infect Genet Evol 19:164–175. http://dx.doi.org/10
.1016/j.meegid.2013.07.009.
66. Mallick PK, Joshi H, Valecha N, Sharma SK, Eapen A, Bhatt RM,
Srivastava HC, Sutton PL, Dash AP, Bhasin VK. 2012. Mutant pfcrt
“SVMNT” haplotype and wild type pfmdr1 “N86” are endemic in Plasmo-
dium vivax dominated areas of India under high chloroquine exposure.
Malar J 11:16. http://dx.doi.org/10.1186/1475-2875-11-16.
67. Foote SJ, Kyle DE, Martin RK, Oduola AM, Forsyth K, Kemp DJ,
Cowman AF. 1990. Several alleles of the multidrug-resistance gene are
closely linked to chloroquine resistance inPlasmodium falciparum. Nature
345:255–258. http://dx.doi.org/10.1038/345255a0.
68. Phompradit P, Muhamad P, Wisedpanichkij R, Chaijaroenkul W, Na-
Bangchang K. 2014. Four years’ monitoring of in vitro sensitivity and
candidate molecular markers of resistance of Plasmodium falciparum to
artesunate-mefloquine combination in the Thai-Myanmar border. Malar
J 13:23. http://dx.doi.org/10.1186/1475-2875-13-23.
69. Beshir K, Sutherland CJ, Merinopoulos I, Durrani N, Leslie T, Rowland
M, Hallett RL. 2010. Amodiaquine resistance in Plasmodium falciparum
malaria in Afghanistan is associated with the pfcrt SVMNT allele at codons
72 to 76. Antimicrob Agents Chemother 54:3714–3716. http://dx.doi.org
/10.1128/AAC.00358-10.
70. Dlamini SV, Beshir K, Sutherland CJ. 2010. Markers of anti-malarial
drug resistance in Plasmodium falciparum isolates from Swaziland: iden-
tification of pfmdr1-86F in natural parasite isolates.Malar J 9:68. http://dx
.doi.org/10.1186/1475-2875-9-68.
71. Chugh M, Scheurer C, Sax S, Bilsland E, van Schalkwyk DA, Wicht KJ,
Hofmann N, Sharma A, Bashyam S, Singh S, Oliver SG, Egan TJ,
Malhotra P, Sutherland CJ, Beck HP, Wittlin S, Spangenberg T, Ding
XC. 2015. Identification and deconvolution of cross-resistance signals
Rao et al.
1510 jcm.asm.org June 2016 Volume 54 Number 6Journal of Clinical Microbiology
from antimalarial compounds using multidrug-resistant Plasmodium fal-
ciparum strains. Antimicrob Agents Chemother 59:1110–1118. http://dx
.doi.org/10.1128/AAC.03265-14.
72. Foote SJ, Thompson JK, Cowman AF, Kemp DJ. 1989. Amplification
of the multidrug resistance gene in some chloroquine-resistant isolates
of P. falciparum. Cell 57:921–930. http://dx.doi.org/10.1016/0092
-8674(89)90330-9.
73. Wilson CM, Volkman SK, Thaithong S, Martin RK, Kyle DE, Milhous
WK, Wirth DF. 1993. Amplification of pfmdr 1 associated with meflo-
quine and halofantrine resistance in Plasmodium falciparum from Thai-
land. Mol Biochem Parasitol 57:151–160. http://dx.doi.org/10.1016/0166
-6851(93)90252-S.
74. Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S,
Fidock DA. 2006. Decreasing pfmdr1 copy number in Plasmodium falcip-
arum malaria heightens susceptibility to mefloquine, lumefantrine, halo-
fantrine, quinine, and artemisinin. J Infect Dis 194:528–535. http://dx.doi
.org/10.1086/507115.
75. Petersen I, Eastman R, Lanzer M. 2011. Drug-resistant malaria: molec-
ular mechanisms and implications for public health. FEBS Lett 585:1551–
1562. http://dx.doi.org/10.1016/j.febslet.2011.04.042.
76. Sibley CH. 2014. Understanding drug resistance in malaria parasites:
basic science for public health. Mol Biochem Parasitol 195:107–114. http:
//dx.doi.org/10.1016/j.molbiopara.2014.06.001.
77. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM,
Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M,
Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P,
Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resis-
tance in Plasmodium falciparummalaria. N Engl JMed 361:455–467. http:
//dx.doi.org/10.1056/NEJMoa0808859.
78. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM,
Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium.
2008. Evidence of artemisinin-resistant malaria in western Cambodia. N
Engl J Med 359:2619–2620. http://dx.doi.org/10.1056/NEJMc0805011.
79. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon
S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM,
Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P,
Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R,
Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT,
Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M,
Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA,
Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi
P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose
A, Hossain MA, Samad R, et al. 2014. Spread of artemisinin resistance
in Plasmodium falciparum malaria. N Engl J Med 371:411–423. http:
//dx.doi.org/10.1056/NEJMoa1314981.
80. Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, Lin K,
Kyaw MP, Plewes K, Faiz MA, Dhorda M, Cheah PY, Pukrittayakamee
S, Ashley EA, Anderson TJ, Nair S, McDew-White M, Flegg JA, Grist
EP, Guerin P, Maude RJ, Smithuis F, Dondorp AM, Day NP, Nosten F,
White NJ, Woodrow CJ. 2015. Spread of artemisinin-resistant Plasmo-
dium falciparum in Myanmar: a cross-sectional survey of the K13 molec-
ular marker. Lancet Infect Dis 15:415–421. http://dx.doi.org/10.1016
/S1473-3099(15)70032-0.
81. Chatterjee M, Ganguly S, Saha P, Bankura B, Basu N, Das M, Guha SK,
Maji AK. 2015. No polymorphism in Plasmodium falciparumK13 propel-
ler gene in clinical isolates from Kolkata, India. J Pathog 2015:374354.
http://dx.doi.org/10.1155/2015/374354.
82. Pelleau S, Moss EL, Dhingra SK, Volney B, Casteras J, Gabryszewski
SJ, Volkman SK, Wirth DF, Legrand E, Fidock DA, Neafsey DE,
Musset L. 2015. Adaptive evolution of malaria parasites in French
Guiana: reversal of chloroquine resistance by acquisition of a mutation
in pfcrt. Proc Natl Acad Sci U S A 112:11672–11677. http://dx.doi.org
/10.1073/pnas.1507142112.
83. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe
PN, Djimdé AA, Kouriba B, Taylor TE, Plowe CV. 2003. Reemergence
of chloroquine-sensitive Plasmodium falciparummalaria after cessation of
chloroquine use in Malawi. J Infect Dis 187:1870–1875. http://dx.doi.org
/10.1086/375419.
84. Moss WJ, Dorsey G, Mueller I, Laufer MK, Krogstad DJ, Vinetz JM,
Guzman M, Rosas-Aguirre AM, Herrera S, Arevalo-Herrera M, Chery
L, Kumar A, Mohapatra PK, Ramanathapuram L, Srivastava HC, Cui L,
Zhou G, Parker DM, Nankabirwa J, Kazura JW, International Centers
of Excellence for Malaria Research. 2015. Malaria epidemiology and
control within the International Centers of Excellence for Malaria Re-
search. Am J Trop Med Hyg 93:5–15. http://dx.doi.org/10.4269/ajtmh.15
-0006.
85. Ding XC, Ubben D, Wells TN. 2012. A framework for assessing the risk
of resistance for anti-malarials in development. Malar J 11:292. http://dx
.doi.org/10.1186/1475-2875-11-292.
86. Riel MA, Kyle DE, Bhattacharjee AK, Milhous WK. 2002. Efficacy of
proton pump inhibitor drugs against Plasmodium falciparum in vitro and
their probable pharmacophores. AntimicrobAgents Chemother 46:2627–
2632. http://dx.doi.org/10.1128/AAC.46.8.2627-2632.2002.
87. Wilson DW, Fowkes FJ, Gilson PR, Elliott SR, Tavul L, Michon P,
Dabod E, Siba PM, Mueller I, Crabb BS, Beeson JG. 2011. Quantifying
the importance of MSP1-19 as a target of growth-inhibitory and protec-
tive antibodies against Plasmodium falciparum in humans. PLoS One
6:e27705. http://dx.doi.org/10.1371/journal.pone.0027705.
88. Sa JM, Twu O, Hayton K, Reyes S, Fay MP, Ringwald P, Wellems TE.
2009. Geographic patterns of Plasmodium falciparum drug resistance dis-
tinguished by differential responses to amodiaquine and chloroquine.
Proc Natl Acad Sci U S A 106:18883–18889. http://dx.doi.org/10.1073
/pnas.0911317106.
Amplicon Sequencing To Survey Malaria Drug Resistance
June 2016 Volume 54 Number 6 jcm.asm.org 1511Journal of Clinical Microbiology
